Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 江苏恩华药业股份有限公司始建于1978年，2008年在深圳证券交易所上市，股票代码002262，为科、工、贸一体化的医药企业，国家精神麻醉类药品定点生产单位，国家高新技术企业，国家医药百强企业，国家技术创新示范企业，国家知识产权示范单位，国家“20年20星”医药质量管理企业明星单位，中国麻醉药品协会副会长单位，江苏省医药行业协会副会长单位，江苏省首批创新型企业，江苏省省长质量奖获奖单位。 公司主要生产经营中枢神经系统用药，战略定位于中枢神经药物领域市场，主要从事中枢神经系统药物的开发、生产和销售，是一家专注于中枢神经药物细分市场的企业，主要类别包括麻醉类、精神类和神经类，通过多年来在产品研发、生产和服务上的不懈努力，公司已建立起完整的中枢神经系统药物产品系列和营销网络，努力打造国内重要的中枢神经系统药物的生产商和销售商。 拥有原料药和制剂药物三个大型现代化医药生产基地，总占地面积900余亩，企业具有经国家认证的原料药、固体制剂、水针剂、冻干粉针剂等车间，具有自动化的片剂、胶囊剂、水针剂、粉针剂十余条生产线。目前具有原料药42种400吨/年；西药制剂100余种，固体制剂60亿片（粒）/年、针剂1亿支/年的生产规模。 根据企业发展战略，努力抓好节能降耗，环境保护，绿色发展，通过了能源管理体系认证（ISO50001）、国际环境认证（ISO14000），大力发展原料药出口业务，进行欧盟等国际认证，努力在国际市场取得一席之地。 公司十分注重技术创新，注重新产品开发，加强产学研联合，集团技术中心为国家认定企业技术中心、省级工程技术研究中心，设有企业院士工作站、国家博士后科研工作站、博士后创新中心、江苏省中枢神经药物研究重点实验室，承担着多项国家级重点科研项目。
Main Business 医药研发、生产和销售。
Legal Representative 孙彭生
Top Executives
董事长：孙彭生
董事：孙家权,杨自亮,陈增良,付卿
独立董事：印晓星,李玉兰,陈国祥
Top 5 Shareholder
Shareholder name Nature Holding Date
徐州恩华投资有限公司流通A股31.50%30/09/2024
孙彭生限售股+流通A股4.87%30/09/2024
陈增良限售股+流通A股3.93%30/09/2024
付卿限售股+流通A股3.93%30/09/2024
杨自亮限售股+流通A股3.69%30/09/2024
Company Secretary 段保州
Solicitors 北京市国宏律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 0516-87661189;0516-87661012
Fax No 0516-87767118
Website www.nhwa-group.com
Email nhwawu@126.com;dbz1966@126.com
Company Address
Register: 江苏省徐州经济技术开发区杨山路18号
Office: 江苏省徐州市经济技术开发区龙湖西路31号恩华科技大厦
Listing Date 23/07/2008
Shares Capital
Shares Capital: 1,016,176,792
Total A Share: 1,016,176,792
Listed A Share: 881,792,550
Non-tradable A Share: 134,384,242
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.030
DPS(RMB)* ¥ 0.320
NBV Per Share(RMB)* ¥ 6.386
Market Capitalization(RMB) 19.770B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.